What are the indications and dosing recommendations for fosfomycin, including adjustments for renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Use of Fosfomycin

Fosfomycin trometamol 3 g as a single oral dose is a first-line treatment option for uncomplicated cystitis in women, offering the advantage of minimal resistance and collateral damage, though it has slightly inferior efficacy compared to nitrofurantoin or trimethoprim-sulfamethoxazole. 1

Primary Indications

Uncomplicated Cystitis in Women

Fosfomycin is specifically recommended for acute uncomplicated cystitis in non-pregnant women. The 2024 European Association of Urology guidelines list it as a first-line option alongside nitrofurantoin and pivmecillinam 1. The IDSA/ESMID guidelines note that while fosfomycin has minimal resistance and low propensity for collateral damage, it demonstrates inferior efficacy compared to standard short-course regimens based on FDA data, with clinical cure rates of approximately 91% versus 93-95% for comparators 2.

Asymptomatic Bacteriuria in Pregnancy

Single-dose fosfomycin trometamol is recommended for screening and treating asymptomatic bacteriuria in pregnant women, though this carries a weak strength rating due to low-quality evidence from older studies 1.

Multidrug-Resistant Organisms

  • VRE urinary tract infections: A single 3 g oral dose is recommended for uncomplicated UTIs due to vancomycin-resistant enterococci (weak recommendation, very low quality evidence) 3
  • CRE infections: Fosfomycin displays good in vitro activity against carbapenem-resistant Enterobacterales and is recommended by ESCMID guidelines for complicated UTI without septic shock 3

Standard Dosing

Oral Fosfomycin Trometamol

  • Uncomplicated cystitis: 3 g single dose 1, 4
  • Administration: Mix granules with water before ingesting; never take in dry form 4
  • Food interaction: Can be taken with or without food, though high-fat meals reduce peak concentration from 32 mcg/mL to 17.6 mcg/mL and delay time to peak from 2 to 4 hours. However, total urinary excretion remains unchanged, maintaining therapeutic urinary concentrations ≥100 mcg/mL for 26 hours regardless 4

Intravenous Fosfomycin (where available)

For serious infections with multidrug-resistant organisms in critically ill patients:

  • Standard dosing: 18-24 g/day divided every 6-8 hours 5
  • High-dose regimens: Up to 8 g every 6 hours for severe infections 6

Renal Dose Adjustments

Oral Formulation

No dose adjustment is required for elderly patients or those with mild-to-moderate renal impairment when using the single 3 g dose for uncomplicated cystitis 4. The FDA label states that in renal insufficiency, the half-life increases from 11 hours (CrCl 54 mL/min) to 50 hours (CrCl 7 mL/min), with urinary recovery decreasing from 32% to 11% 4.

Intravenous Formulation

For critically ill patients requiring IV fosfomycin:

  • Normal renal function (CrCl ≥60 mL/min): 20-24 g/day achieves targets for MIC ≤32 μg/mL 7
  • Renal impairment (CrCl <130 mL/min): 8 g three times daily is sufficient for fosfomycin-susceptible pathogens (MIC ≤16 mg/L) 6
  • Continuous renal replacement therapy (CRRT):
    • For Klebsiella pneumoniae (MIC 64 mg/L): 8 g every 12 hours 5
    • For Pseudomonas aeruginosa: 7 g every 8 hours 5
  • Prolonged intermittent renal replacement therapy (PIRRT): 5 g every 8 hours, as dialysis clearance is 183 mL/min, removing approximately 74% of the dose 8

Critical caveat: Drug accumulation occurs with repeated dosing in renal impairment despite dialysis, requiring careful monitoring 8.

Treatment Duration

  • Uncomplicated cystitis: Single dose (clear recommendation) 9
  • Pyelonephritis: Insufficient evidence for oral fosfomycin; IV formulation may be reasonable but lacks strong supporting data 9
  • Bacteremic UTI: 4 g every 6 hours for non-critically ill patients with multidrug-resistant E. coli 10

Important Limitations and Caveats

Efficacy Concerns

The microbiologic cure rate with fosfomycin (78-86%) is lower than nitrofurantoin (86-92%) or trimethoprim-sulfamethoxazole (91-100%), though clinical cure rates are comparable 2. This discrepancy between clinical and microbiologic outcomes should be considered when treating recurrent infections.

Not Recommended For

  • Men with UTI: Not included in treatment recommendations; trimethoprim-sulfamethoxazole for 7 days is preferred 1
  • Pyelonephritis: Oral fosfomycin lacks adequate evidence for upper tract infections 9
  • Complicated UTI requiring hospitalization: Use IV formulation if available, or alternative agents

Drug Interactions

Metoclopramide significantly lowers serum concentrations and urinary excretion of fosfomycin; avoid co-administration 4. Cimetidine does not affect fosfomycin pharmacokinetics 4.

Resistance Considerations

While fosfomycin maintains excellent activity with minimal cross-resistance to other antibiotic classes, susceptibility testing is not routinely performed in many laboratories 2. For empirical therapy, local resistance patterns should guide use, though resistance rates generally remain low even in regions with frequent fosfomycin use 2.

References

10
Research

Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018

Related Questions

What is the appropriate fosfomycin dosing regimen for adults with chronic kidney disease at different levels of renal function (eGFR ≥30 mL/min/1.73 m², eGFR <30 mL/min/1.73 m², and those on intermittent hemodialysis), for both oral and intravenous administration?
What is the recommended fosfomycin dosing for an adult with suspected pyelonephritis and a serum creatinine of 1.5 mg/dL (estimated creatinine clearance ~60–80 mL/min)?
What is the appropriate fosfomycin dosing for a patient with an estimated glomerular filtration rate of 48 mL/min/1.73 m² (moderate renal impairment)?
What is the recommended intravenous fosfomycin dosing for adults (including adjustments for renal impairment) and for pediatric patients?
How should oral fosfomycin tromethamine be administered, including dose, preparation, timing, and considerations for renal impairment and pediatric patients?
Which UpToDate articles on the Breast Imaging Reporting and Data System (BI‑RADS) should I read and how can I access them?
Should I prescribe Kenalog (triamcinolone) for a female patient with left ear redness, tenderness, swollen lymph nodes, and five days of symptoms suggestive of infection?
Is low‑dose naltrexone (LDN) an appropriate treatment for Hashimoto’s thyroiditis, and what dosing regimen should be used?
Does a percutaneous trans‑hepatic cholangiogram (PTC) require the patient to be nil per os (NPO)?
Is apixaban (Eliquis) appropriate for patients on chronic dialysis?
Does semaglutide (Ozempic) cause muscle weakness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.